Shattuck Labs Extends Cash Runway to 2029 and Advances Lead Drug Candidate SL-325

summarizeSummary

Shattuck Labs announced financial results for Q4 and full-year 2025, projecting a cash runway into 2029, and provided positive updates on its lead drug candidate, SL-325, with Phase 1 data expected in Q2 2026 and Phase 2 initiation in Q3 2026.

check_boxKey Events

• Cash Runway Extended to 2029

  The company projects its current cash and investments, including recent ATM proceeds, will fund operations into 2029, significantly de-risking its financial outlook.

• SL-325 Clinical Trial Progress

  The Phase 1 clinical trial for SL-325 is nearing completion, with data expected in the second quarter of 2026. A Phase 2 trial in Crohn's disease is anticipated to initiate in the third quarter of 2026.

• Q1 2026 At-The-Market (ATM) Sales

  Shattuck Labs sold common stock for aggregate gross proceeds of $21.4 million in the first quarter of 2026 under its existing ATM offering facility, contributing to the extended cash runway.

• Reduced Net Loss in 2025

  The company reported a net loss of $48.8 million for the full year 2025, a significant reduction from $75.4 million in 2024, driven by lower R&D and G&A expenses.

auto_awesomeAnalysis

Shattuck Labs has significantly de-risked its financial position by extending its cash runway into 2029, a critical factor for a clinical-stage biotechnology company. This extended runway, partially funded by $21.4 million in Q1 2026 ATM sales, provides substantial operational flexibility. Concurrently, the company reported strong progress for its lead drug candidate, SL-325, with Phase 1 trial data expected in Q2 2026 and a Phase 2 trial in Crohn's disease anticipated to start in Q3 2026. The reduced net loss for 2025 also indicates improved financial management. These combined factors present a strong positive outlook for the company's stability and pipeline development.